Douglas C. Wolf

7.7k total citations · 1 hit paper
209 papers, 5.8k citations indexed

About

Douglas C. Wolf is a scholar working on Cancer Research, Health, Toxicology and Mutagenesis and Genetics. According to data from OpenAlex, Douglas C. Wolf has authored 209 papers receiving a total of 5.8k indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Cancer Research, 38 papers in Health, Toxicology and Mutagenesis and 38 papers in Genetics. Recurrent topics in Douglas C. Wolf's work include Carcinogens and Genotoxicity Assessment (38 papers), Inflammatory Bowel Disease (30 papers) and Microscopic Colitis (16 papers). Douglas C. Wolf is often cited by papers focused on Carcinogens and Genotoxicity Assessment (38 papers), Inflammatory Bowel Disease (30 papers) and Microscopic Colitis (16 papers). Douglas C. Wolf collaborates with scholars based in United States, United Kingdom and Canada. Douglas C. Wolf's co-authors include Thomas L. Goldsworthy, Jeffrey I. Everitt, Susan Hester, Michael H. George, Tanya Moore, Sheau‐Fung Thai, Stephen Nesnow, Amber K. Goetz, Anthony B. DeAngelo and Byron E. Butterworth and has published in prestigious journals such as Science, New England Journal of Medicine and SHILAP Revista de lepidopterología.

In The Last Decade

Douglas C. Wolf

204 papers receiving 5.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis

2016 360 citations Douglas C. Wolf, Geert D’Haens et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Douglas C. Wolf United States	42	1.6k	1.4k	1.1k	792	581	209	5.8k
Robert Barouki France	44	2.5k 1.5×	2.3k 1.6×	759 0.7×	555 0.7×	415 0.7×	189	7.1k
Gary A. Boorman United States	41	1.8k 1.1×	1.8k 1.2×	1.8k 1.7×	355 0.4×	901 1.6×	200	6.8k
Hideki Wanibuchi Japan	40	1.0k 0.6×	2.7k 1.9×	1.3k 1.2×	261 0.3×	431 0.7×	305	6.2k
Paul L. Carmichael United Kingdom	42	1.2k 0.7×	1.8k 1.2×	1.2k 1.1×	608 0.8×	444 0.8×	164	5.5k
David Warshawsky United States	29	1.4k 0.9×	3.6k 2.5×	1.6k 1.5×	929 1.2×	419 0.7×	115	7.5k
Russell C. Cattley United States	39	1.5k 0.9×	2.6k 1.8×	1.1k 1.0×	481 0.6×	320 0.6×	105	5.6k
Kirsi Vähäkangas Finland	43	1.1k 0.7×	1.8k 1.3×	1.4k 1.3×	242 0.3×	272 0.5×	202	6.4k
Nathaniel Rothman United States	52	3.0k 1.9×	2.5k 1.8×	3.0k 2.7×	693 0.9×	376 0.6×	196	8.8k
Jon C. Cook United States	27	1.3k 0.8×	867 0.6×	456 0.4×	478 0.6×	325 0.6×	70	5.4k
Olivier Fardel France	52	1.3k 0.8×	2.4k 1.7×	635 0.6×	261 0.3×	1.4k 2.3×	214	8.3k

Countries citing papers authored by Douglas C. Wolf

Since Specialization

Citations

This map shows the geographic impact of Douglas C. Wolf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Douglas C. Wolf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Douglas C. Wolf more than expected).

Fields of papers citing papers by Douglas C. Wolf

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Douglas C. Wolf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Douglas C. Wolf. The network helps show where Douglas C. Wolf may publish in the future.

Co-authorship network of co-authors of Douglas C. Wolf

This figure shows the co-authorship network connecting the top 25 collaborators of Douglas C. Wolf. A scholar is included among the top collaborators of Douglas C. Wolf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Douglas C. Wolf. Douglas C. Wolf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Danese, Silvio, et al.. (2023). P405 Long-term safety of 3 years of ozanimod in moderately to severely active ulcerative colitis: an interim analysis of the True North open-label extension. Journal of Crohn s and Colitis. 17(Supplement_1). i534–i535. 3 indexed citations

Wolf, Douglas C., et al.. (2023). P50 A phase 1/2 randomized, placebo-controlled, multiple ascending dose study (ACHIEVE) of DYNE-101 in individuals with myotonic dystrophy type 1 (DM1). Neuromuscular Disorders. 33. S71–S71. 1 indexed citations

D’Haens, Geert, Marla C. Dubinsky, Laurent Peyrin‐Biroulet, et al.. (2023). P632 Etrasimod induction therapy in moderately to severely active Crohn’s disease: results from a phase 2, randomised, double-blind substudy. Journal of Crohn s and Colitis. 17(Supplement_1). i764–i765. 14 indexed citations

Danese, Silvio, et al.. (2023). DOP37 Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension study. Journal of Crohn s and Colitis. 17(Supplement_1). i101–i102. 4 indexed citations

Siegmund, Britta, Silvio Danese, J.F. Colombel, et al.. (2022). Long-term use of ozanimod in patients with moderately to severely active ulcerative colitis. Zeitschrift für Gastroenterologie. 60(8). e428–e428. 2 indexed citations

Mistry, Pratibha, et al.. (2021). An evaluation of carcinogenicity predictors from short-term and sub chronic repeat-dose studies of agrochemicals in rats: Opportunities to refine and reduce animal use. Toxicology Letters. 351. 18–27. 3 indexed citations

Parish, Stanley T., Michael Aschner, Warren Casey, et al.. (2020). An evaluation framework for new approach methodologies (NAMs) for human health safety assessment. Regulatory Toxicology and Pharmacology. 112. 104592–104592. 135 indexed citations

Cohen, Samuel M., Alan R. Boobis, Vicki L. Dellarco, et al.. (2019). Chemical carcinogenicity revisited 3: Risk assessment of carcinogenic potential based on the current state of knowledge of carcinogenesis in humans. Regulatory Toxicology and Pharmacology. 103. 100–105. 71 indexed citations

Stanko, Jason P., Jennifer L. Rayner, Christine Davis, et al.. (2010). Effects of prenatal exposure to a low dose atrazine metabolite mixture on pubertal timing and prostate development of male Long-Evans rats. Reproductive Toxicology. 30(4). 540–549. 41 indexed citations

10.

Moran, John R., Kosali Simon, Timothy M. Smeeding, et al.. (2005). Income and the Use of Prescription Drugs by the Elderly. SSRN Electronic Journal.

11.

McDorman, Kevin S., Brian F. Pachkowski, Jun Nakamura, Douglas C. Wolf, & James A. Swenberg. (2005). Oxidative DNA damage from potassium bromate exposure in Long-Evans rats is not enhanced by a mixture of drinking water disinfection by-products. Chemico-Biological Interactions. 152(2-3). 107–117. 27 indexed citations

12.

Orangio, Guy R., et al.. (2005). Crohn's Colitis Presenting With Node-Negative Colon Cancer and Liver Metastasis After Therapy With Infliximab: Report of Two Cases. Diseases of the Colon & Rectum. 48(8). 1651–1655. 8 indexed citations

13.

Guinn, Debra A., Jill Davies, Richard O. Jones, Lisa Sullivan, & Douglas C. Wolf. (2004). Labor induction in women with an unfavorable Bishop score: Randomized controlled trial of intrauterine Foley catheter with concurrent oxytocin infusion versus Foley catheter with extra-amniotic saline infusion with concurrent oxytocin infusion. American Journal of Obstetrics and Gynecology. 191(1). 225–229. 22 indexed citations

14.

Wolf, Douglas C., et al.. (2004). The transcriptional profile of the kidney in Tsc2 heterozygous mutant Long Evans (Eker) rats compared to wild-type. Mutation research. Fundamental and molecular mechanisms of mutagenesis. 549(1-2). 213–224. 8 indexed citations

15.

McDorman, Kevin S., Michelle J. Hooth, Thomas B. Starr, & Douglas C. Wolf. (2003). Analysis of preneoplastic and neoplastic renal lesions in Tsc2 mutant Long–Evans (Eker) rats following exposure to a mixture of drinking water disinfection by-products. Toxicology. 187(1). 1–12. 13 indexed citations

16.

Wolf, Douglas C., et al.. (2000). Promotion by sodium barbital induces early development but does not increase the multiplicity of hereditary renal tumors in Eker rats. Carcinogenesis. 21(8). 1553–1558. 8 indexed citations

17.

Wolf, Douglas C.. (2000). IBD Highlights from the 1999 American College of Gastroenterology Meeting: Infliximab and 6-MP. Inflammatory Bowel Diseases. 6(1). 59–60. 3 indexed citations

18.

Moser, Glenda J., Brian A. Wong, Douglas C. Wolf, Ronny Fransson-Steen, & Thomas L. Goldsworthy. (1996). Methyl tertiary butyl ether lacks tumor-promoting activity in N-nitrosodiethylamine-initiated B6C3F1 female mouse liver. Carcinogenesis. 17(12). 2753–2761. 15 indexed citations

19.

Shivapurkar, Narayan, Steven A. Belinsky, Douglas C. Wolf, Zhaocheng Tang, & Oliver Alabaster. (1995). Absence of p53 gene mutations in rat colon carcinomas induced by azoxymethane. Cancer Letters. 96(1). 63–70. 27 indexed citations

20.

Larson, Jeffrey L., et al.. (1994). Nasal Toxicity of Chloroform in Male F-344 Rats and Female B6C3F1 Mice Following a 1-Week Inhalation Exposure. Toxicology and Applied Pharmacology. 125(2). 214–227. 37 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact